NRIX Earnings & Financial Statements
Nurix Therapeutics, Inc.
$23.67
+$1.54(+6.96%)
55
Overall
60
Value
54
Tech
52
Quality
Market Cap
$2.59B
Volume
2.98M
52W Range
$9.00 - $28.23
Target Price
$34.36
NRIX earnings and financial statements: Nurix Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NRIX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $83.98M | $54.55M | $76.99M | $38.63M | $29.75M |
| Operating income | -$285.67M | -$213.03M | -$155.06M | -$183.87M | -$117.89M |
| EBITDA | -$244.88M | -$176.89M | -$130.33M | -$169.60M | -$111.80M |
| Net income | -$264.46M | -$193.57M | -$143.95M | -$180.36M | -$117.19M |
| EPS (diluted) | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $688.13M | $669.34M | $355.60M | $416.76M | $476.77M |
| Total liabilities | $149.39M | $142.35M | $155.10M | $113.06M | $134.47M |
| Shareholders’ equity | $538.75M | $526.99M | $200.49M | $303.70M | $342.30M |
| Cash and equivalents | $246.96M | $110.00M | $54.63M | $64.47M | $80.51M |
| Long-term debt | $52.91M | $20.29M | $23.13M | $6.43M | $9.19M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$249.47M | -$172.58M | -$81.36M | -$159.81M | -$84.36M |
| Capital expenditure | -$14.00M | -$9.27M | -$8.40M | -$12.24M | -$5.66M |
| Free cash flow | -$263.47M | -$181.86M | -$89.77M | -$172.05M | -$90.03M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NRIX | $23.67 | +7.0% | 2.98M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Nurix Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW